Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Myriad Genetics Inc (MYGN)
Price$4.29Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 · Dec 31 | 2020 · Jun 30 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $557.1M | $638.6M | $851.1M | $743.7M | $728.7M | $740.5M | $722.5M | $778.2M | $613.2M | $496.0M | $402.1M | $362.6M | $326.5M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — | — | — | — | — | $583.5M | $607.7M | $589.7M | $682.1M | $548.8M | $444.6M | $356.4M | $318.4M | $283.3M |
| Gross margin | 69.93% | 69.89% | 68.64% | 70.22% | — | — | — | — | — | 80.07% | 82.07% | 81.62% | 87.65% | 89.50% | 89.63% | 88.65% | 87.79% | 86.75% |
| Research & development | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M | $73.3M | $77.2M | $85.9M | $70.8M | $74.4M | $70.6M | $75.5M | $67.5M | $53.7M | $42.6M | $27.8M | $21.9M | $17.9M |
| Operating expenses | $963.8M | $708.9M | $1.01B | $819.0M | $881.1M | $846.8M | $870.3M | $843.5M | $621.8M | $684.7M | $587.1M | $588.9M | $503.8M | $385.2M | $315.7M | $244.3M | $227.6M | $200.1M |
| Operating income | −$387.2M | −$123.5M | −$257.4M | −$140.6M | −$190.5M | −$289.7M | −$231.7M | $7.6M | $121.9M | $44.0M | $153.4M | $133.6M | $274.4M | $228.0M | $180.3M | $157.8M | $135.1M | $126.5M |
| Operating margin | −46.96% | −14.74% | −34.17% | −20.73% | −27.58% | −52.00% | −36.28% | 0.89% | 16.39% | 6.04% | 20.72% | 18.49% | 35.26% | 37.18% | 36.35% | 39.24% | 37.25% | 38.73% |
| EBITDA | −$333.5M | −$62.3M | −$195.5M | −$87.9M | −$127.7M | −$253.9M | −$159.7M | $80.6M | $176.3M | $92.3M | $180.2M | $158.6M | $288.2M | $236.9M | $189.4M | $165.0M | $142.2M | $135.9M |
| EBITDA margin | −40.45% | −7.44% | −25.96% | −12.96% | −18.49% | −45.58% | −25.01% | 9.47% | 23.71% | 12.67% | 24.33% | 21.95% | 37.03% | 38.63% | 38.18% | 41.04% | 39.20% | 41.62% |
| Net income | −$365.9M | −$127.3M | −$263.3M | −$112.0M | −$27.2M | −$223.6M | −$199.5M | $4.6M | $133.3M | $17.4M | $117.2M | $79.8M | $176.2M | $147.2M | $112.2M | $100.7M | $152.3M | $84.6M |
| Net profit margin | −44.38% | −15.20% | −34.96% | −16.51% | −3.94% | −40.14% | −31.24% | 0.54% | 17.92% | 2.39% | 15.83% | 11.04% | 22.64% | 24.01% | 22.61% | 25.05% | 42.00% | 25.91% |
| Basic EPSper basic share | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | -$2.69 | $0.06 | $1.92 | $0.25 | $1.67 | $1.12 | $2.33 | $1.82 | $1.33 | $1.12 | $1.58 | $0.91 |
| Diluted EPSper diluted share | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | -$2.69 | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 | $2.25 | $1.77 | $1.30 | $1.10 | $1.54 | $0.86 |
Owners
Reported shareholders
11.39%of listed shares
BlackRock, Inc.10.89M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 11.39%10.89M shares |
MILLENNIUM MANAGEMENT LLC | 6.93%6.62M shares |
Vestal Point Capital, LP | 6.00%5.74M shares |
STATE STREET CORP | 5.21%4.99M shares |
D. E. Shaw & Co., Inc. | 4.79%4.58M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.27%4.08M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.27%3.13M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.22%3.08M shares |
AQR CAPITAL MANAGEMENT LLC | 2.89%2.77M shares |
MORGAN STANLEY | 2.60%2.48M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.53%2.42M shares |
Assenagon Asset Management S.A. | 2.16%2.06M shares |
GOLDMAN SACHS GROUP INC | 2.15%2.06M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.98%1.89M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.82%1.74M shares |
Qube Research & Technologies Ltd | 1.74%1.67M shares |
FEDERATED HERMES, INC. | 1.64%1.57M shares |
TWO SIGMA INVESTMENTS, LP | 1.63%1.56M shares |
Nuveen, LLC | 1.62%1.55M shares |
MACKENZIE FINANCIAL CORP | 1.61%1.54M shares |
Percentages use 95.6M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 · 10b5-1 | Kumar RashmiDirector | SellCommon Stock | 15.0K | $4.46 | $66.9K | 171.9K |
| May 14, 2026Form 4 | Bisaro PaulDirector | BuyCommon Stock | 7.5K | $3.69 | $27.7K | 97.4K |
| Mar 9, 2026Form 4 | Raha Samraat S.President and CEO | BuyCommon Stock | 40.0K | $5.00 | $200.0K | 493.1K |
| Feb 27, 2026Form 4 | Phanstiel S. LouiseDirector | BuyCommon Stock | 48.0K | $4.66 | $223.7K | 282.0K |
| Feb 26, 2026Form 4 | Phanstiel S. LouiseDirector | BuyCommon Stock | 50.4K | $4.80 | $242.0K | 234.0K |